DB19061InvestigationalProtein Based Therapies
Nezastomig is under investigation in clinical trial NCT06085664 (A Pilot Presurgical Trial of REGN5678 (Anti-psma X CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy).
- Mechanism
- Curator reviewed
Pharmacologically active on Glutamate carboxypeptidase 2 and T-cell-specific surface glycoprotein CD28
- Also known as
- Anti-psma/cd28 bispecific antibody regn5678
- Code names
- REGN-5678
Resolves to
Compound
Targets
What you can answer from here — as of July 09, 2026
Which drugs share a target with Nezastomig, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account